American Heart Journal
Volume 153, Issue 1 , Pages 59-65 , January 2007

Comparison of measures of medication persistency using a prescription drug database

  • Marie Hudson, MD, MPH

      Affiliations

    • Corresponding Author InformationReprint requests: Marie Hudson, MD, MPH, Division of Clinical Epidemiology, L-10 421, The Research Institute of the McGill University Health Centre, 1650 Cedar Ave, Montreal, Quebec, Canda H3G 1A4.
    • ,
  • Elham Rahme, PhD
    • ,
  • Hugues Richard, MSc
    • ,
  • Louise Pilote, MD, MPH, PhD

Received 11 May 2006 ,Accepted 23 October 2006.

References 

  1. World Health Organization . Adherence to long-term therapies: evidence for action. Geneva: World Health Organisation; 2003;
  2. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074–1090
  3. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–116
  4. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–574
  5. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:453–460
  6. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary-care settings. N Engl J Med. 1995;332:1125–1131
  7. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications—a cross-national study. JAMA. 1998;279:1458–1462
  8. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–461
  9. Jackevicius CA, Mamdami M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462–467
  10. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002;88:229–233
  11. Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005;59:564–573
  12. Blackburn DE, Dobson RT, Blackburn JL, et al. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25:1035–1043
  13. Hudson M, Baron M, Rahme E, et al. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol. 2005;32:1589–1593
  14. Pilote L, Abrahamowicz M, Rodrigues E, et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?. Ann Intern Med. 2004;141:102–112
  15. Zhou Z, Rahme E, Abrahamowicz M, et al. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol. 2005;162:1016–1023
  16. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiologic research—the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48:999–1009
  17. Applegate WB. Elderly patients' adherence to statin therapy. JAMA. 2002;288:495–497

 Drs Hudson and Pilote are funded by the Canadian Institutes of Health Research. Dr Pilote is a William Dawson Professor of Medicine at McGill University, Montreal, Quebec, Canada. This study was supported in part by a grant from the Canadian Institutes of Health Research (#ATF 6669).

 Dr Hudson was responsible for the conception of the study. Dr Pilote was responsible for acquisition of the data. Mr Richard was responsible for the data programming. All authors were responsible for the design of the study, data analysis, and interpretation. Dr Hudson was responsible for drafting the manuscript. All other authors were responsible for revising the manuscript critically for important intellectual content. All authors have seen and approved the final version of the manuscript.

 None of the authors have any conflicts of interests to disclose.

 The funding agency had no role in the design of the study; in the collection, analysis, and interpretation of the data; in the writing of the manuscript; and in the decision to submit the article for publication.

PII: S0002-8703(06)00930-6

doi: 10.1016/j.ahj.2006.10.018

American Heart Journal
Volume 153, Issue 1 , Pages 59-65 , January 2007

Article Tools

* Image Usage & Resolution